Status:
RECRUITING
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
Lead Sponsor:
Sun Yat-sen University
Conditions:
Antibody-drug Conjugates
HER2-low Breast Cancer
Eligibility:
All Genders
Brief Summary
This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+/2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs). Key variables include pa...
Detailed Description
Breast cancer is one of the most common malignancies in women, posing a significant threat to female health. According to current molecular subtypes, breast cancer is classified into hormone receptor-...
Eligibility Criteria
Inclusion
- Diagnosed with HER2-low breast cancer, defined as immunohistochemistry (IHC) score of 1+ or IHC score of 2+ with negative in situ hybridization (FISH-negative)
- Received sequential administration of two or more ADCs
- Complete data for patient's character, laboratory and imaging test, treatment and follow-up are available.
Exclusion
- Concomitant with other tumor components at the time of diagnosis;
- Have a history of any other malignant tumors;
- Lack of complete data
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT06877416
Start Date
January 1 2020
End Date
January 1 2026
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun yat-sen University Cancer
Guangzhou, Guangdong, China, 510060